<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00299390</url>
  </required_header>
  <id_info>
    <org_study_id>91375</org_study_id>
    <secondary_id>2005-000597-53</secondary_id>
    <secondary_id>307972</secondary_id>
    <nct_id>NCT00299390</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Study to Investigate the Efficacy and Safety of ZK 219477 as First Line Therapy in Chemotherapy Naive Patients With Extensive Disease (ED) Stage Small Cell Lung Cancer (SCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the study drug is effective and safe in the
      first line treatment of patients with small cell lung cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
      renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor
      of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Since only 1 of the first 10 subjects responded to the study treatment, it was decided to stop
    the trial due to lack of efficacy .
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response to treatment according to the modRECIST (complete response or partial response)</measure>
    <time_frame>Every 2 cycles until tumor progression i.e. approximately every 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of complete or partial tumor response</measure>
    <time_frame>Every 2 cycles until tumor progression i.e. approximately every 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression</measure>
    <time_frame>Every 2 cycles until tumor progression i.e. approximately every 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Approximately 30 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sagopilone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sagopilone (BAY86-5302, ZK 219477)</intervention_name>
    <description>Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion</description>
    <arm_group_label>Sagopilone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven Small-cell lung cancer (SCLC)

          -  Stage of extensive disease defined by the presence of distant metastases

          -  At least 1 unidimensionally measureable lesion

          -  WHO performance status 0 to 1

          -  No previous SCLC-related chemotherapy

          -  No previous SCLC-related surgery

          -  No previous radiotherapy (excepting for brain metastasis)

          -  Adequate function of major organs and systems

               -  Nervous system

                    -  No Grade 2 or greater peripheral neuropathy

               -  Cardiovascular:

                    -  No symptomatic congestive heart failure

                    -  No unstable angina pectoris

                    -  No arrythmia needing continuous treatment

                    -  No other uncontrolled concurrent illness

        Exclusion Criteria:

          -  Superior vena cava syndrome or obstruction of any vital structure

          -  Untreated malignant hypercalcemia

          -  Pleural effusion as the only manifestation of disease

          -  Extensive disease amenable to radiation therapy

          -  Symptomatic brain metastases requiring whole brain irradiation

          -  Any concomitant malignancy excepting non-melanoma skin cancer or carcinoma in situ of
             the cervix
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe.</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2006</study_first_submitted>
  <study_first_submitted_qc>March 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2006</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sagopilone</keyword>
  <keyword>Epothilone</keyword>
  <keyword>SCLC</keyword>
  <keyword>Small Cell Lung Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epothilones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

